Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Shanthi Rexaline

Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock

Moderna, Inc. (NASDAQ:MRNA) reported better-than-expected fourth-quarter earnings Thursday and announced a slight upward revision to its vaccine sales forecast for 2022. The company also announced a $3-billion stock buyback.

The stock rallied 15.1% in Thursday's trading session. Here's what two analysts had to say about the earnings results. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.